Debra Ritzwoller to Lung Neoplasms
This is a "connection" page, showing publications Debra Ritzwoller has written about Lung Neoplasms.
Connection Strength
10.428
-
Examining trends in lung cancer screening over 10?years: Eligibility, participation, cancer detection, and quality implications. Cancer. 2025 Dec 15; 131(24):e70211.
Score: 0.709
-
Patterns of recurrence among adults diagnosed with screen-detected lung cancer. Cancer Epidemiol. 2025 Apr; 95:102777.
Score: 0.670
-
Development of an Electronic Health Record-Based Algorithm for Predicting Lung Cancer Screening Eligibility in the Population-Based Research to Optimize the Screening Process Lung Research Consortium. JCO Clin Cancer Inform. 2023 Sep; 7:e2300063.
Score: 0.605
-
Individuals Eligible for Lung Cancer Screening Less Likely to Receive Screening When Enrolled in Health Plans With Deductibles. Med Care. 2023 Oct 01; 61(10):665-673.
Score: 0.602
-
Smoking status and the association between patient-level factors and survival among lung cancer patients. J Natl Cancer Inst. 2023 08 08; 115(8):937-948.
Score: 0.602
-
Uptake of novel systemic therapy: Real world patterns among adults with advanced non-small cell lung cancer. Cancer Treat Res Commun. 2023; 36:100730.
Score: 0.596
-
Stage Migration and Lung Cancer Incidence After Initiation of Low-Dose Computed Tomography Screening. J Thorac Oncol. 2022 12; 17(12):1355-1364.
Score: 0.565
-
A Feasible Path to Reductions in Racial and Ethnic Disparities in Lung Cancer Screening? JNCI Cancer Spectr. 2022 May 02; 6(3).
Score: 0.551
-
Evaluation of Population-Level Changes Associated With the 2021 US Preventive Services Task Force Lung Cancer Screening Recommendations in Community-Based Health Care Systems. JAMA Netw Open. 2021 10 01; 4(10):e2128176.
Score: 0.530
-
Real-world Clinical Implementation of Lung Cancer Screening-Evaluating Processes to Improve Screening Guidelines-Concordance. J Gen Intern Med. 2020 04; 35(4):1143-1152.
Score: 0.471
-
Evaluating Lung Cancer Screening Across Diverse Healthcare Systems: A Process Model from the Lung PROSPR Consortium. Cancer Prev Res (Phila). 2020 02; 13(2):129-136.
Score: 0.468
-
Spending for Advanced Cancer Diagnoses: Comparing Recurrent Versus De Novo Stage IV Disease. J Oncol Pract. 2019 07; 15(7):e616-e627.
Score: 0.449
-
Medical Care Costs for Recurrent versus De Novo Stage IV Cancer by Age at Diagnosis. Health Serv Res. 2018 12; 53(6):5106-5128.
Score: 0.425
-
Detecting Lung and Colorectal Cancer Recurrence Using Structured Clinical/Administrative Data to Enable Outcomes Research and Population Health Management. Med Care. 2017 12; 55(12):e88-e98.
Score: 0.406
-
Survival after recurrence of stage I-III breast, colorectal, or lung cancer. Cancer Epidemiol. 2017 08; 49:186-194.
Score: 0.395
-
Effect of Angiotensin System Inhibitors on Survival in Patients Receiving Chemotherapy for Advanced Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2017 03; 18(2):189-197.e3.
Score: 0.372
-
Use of Bevacizumab in Community Settings: Toxicity Profile and Risk of Hospitalization in Patients With Advanced Non-Small-Cell Lung Cancer. J Oncol Pract. 2015 Sep; 11(5):356-62.
Score: 0.342
-
Comparative effectiveness of adjunctive bevacizumab for advanced lung cancer: the cancer research network experience. J Thorac Oncol. 2014 May; 9(5):692-701.
Score: 0.317
-
Patterns and predictors of first-line chemotherapy use among adults with advanced non-small cell lung cancer in the cancer research network. Lung Cancer. 2012 Dec; 78(3):245-52.
Score: 0.284
-
Radiation Dose Associated With CT in the Watch the Spot Trial: A Pragmatic Trial of Less Versus More Intensive Strategies for Active Follow-Up of Patients With Small Pulmonary Nodules. J Am Coll Radiol. 2025 12; 22(12):1578-1588.
Score: 0.177
-
Baseline Characteristics of Participants and Pulmonary Nodules in the Watch the Spot Trial: A Pragmatic Trial of Less versus More Intensive Strategies for Active Surveillance of Patients With Small Pulmonary Nodules. Clin Lung Cancer. 2025 Sep; 26(6):e472-e482.e1.
Score: 0.170
-
Adherence to Annual Lung Cancer Screening and Rates of Cancer Diagnosis. JAMA Netw Open. 2025 Mar 03; 8(3):e250942.
Score: 0.168
-
Rates of Downstream Procedures and Complications Associated With Lung Cancer Screening in Routine Clinical Practice : A Retrospective Cohort Study. Ann Intern Med. 2024 Jan; 177(1):18-28.
Score: 0.155
-
Evaluating and Improving Cancer Screening Process Quality in a Multilevel Context: The PROSPR II Consortium Design and Research Agenda. Cancer Epidemiol Biomarkers Prev. 2022 08 02; 31(8):1521-1531.
Score: 0.140
-
Monitoring Lung Cancer Screening Use and Outcomes at Four Cancer Research Network Sites. Ann Am Thorac Soc. 2017 Dec; 14(12):1827-1835.
Score: 0.102
-
Validating billing/encounter codes as indicators of lung, colorectal, breast, and prostate cancer recurrence using 2 large contemporary cohorts. Med Care. 2014 Oct; 52(10):e65-73.
Score: 0.082
-
Validation of electronic data on chemotherapy and hormone therapy use in HMOs. Med Care. 2013 Oct; 51(10):e67-73.
Score: 0.076